Long-term follow-up of patients with epithelial carcinoma of the ovary.
To determine the long-term outcomes of patients with epithelial ovarian cancer. A group of 298 patients with epithelial ovarian cancer were treated with combination chemotherapy between July 1979 and January 1986 at the Tokai Ovarian Tumor Study Group. Long-term results of these patients were analyzed. Five-year survival and 10-year survival rates of all the patients were 53% and 47%, respectively. Five-year survival and 10-year survival rates for stage I were 89% and 79%, 59% and 56% for stage II, 27% and 22% for stage III, and 9% and 9% for stage IV, respectively. Survival of mucinous and endometrioid cell types were decreased after 5 or more years. In stages II-IV, cisplatin-based chemotherapy produced better results than mitomycin-C, 5-Fu, cytarabine (MFC) therapy. Long-term results of epithelial ovarian cancer were not favorable even in mucinous and endometrioid cell types. For long-term results, cisplatin-based chemotherapy was effective in advanced ovarian cancer. Long-term follow-up of ovarian cancer is important and necessary.